Advertisement

Organisation › Details
Ipsen Pharma GmbH
Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million, representing about 15% of Group sales. The Group has more than 4,500 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. *
![]() |
Start | 1997-01-01 existent |
Group | Ipsen (Group) | |
![]() |
Industry | pharmaceutical |
![]() |
Region | Ettlingen |
Country | Germany | |
Street | 30 Einsteinstr. | |
City | 76275 Ettlingen | |
Tel | +49-7243-184-80 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2025-03-16 |
Advertisement

More documents for Ipsen (Group)
- [1] Santhera Pharmaceuticals Holding AG. (11/4/21). "Press Release: Santhera Appoints Stephanie Brown as President North America and Member of the Executive Management Team". Pratteln....
- [2] Ipsen S.A.. (9/25/20). "Press Release: Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer". Paris....
- [3] Ipsen S.A.. (12/18/19). "Press Release: Ipsen Announces Departure of David Meek as Chief Executive Officer". Paris....
- [4] Ferring Pharmaceuticals S.A.. (12/18/19). "Press Release: FerGene Appoints David Meek Chief Executive Officer". Cambridge, MA....
- [5] Debiopharm International SA. (6/12/19). "Press Release: Debiopharm and Ipsen Extend Their Strategic Decapeptyl (triptorelin) Partnership for another 15 Years". Lausanne & Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top